Canada: Pharmacapsules @ Gowlings – August 2007

Last Updated: August 24 2007

Edited by Jennifer Wilkie and Chantal Saunders


  • Health Canada Reminds Consumers About the Risks of Buying Drugs Online
  • U.K. Published New Guidelines for Early Stage-Clinical Trials
  • Apotex AIDS Drug Costlier than Other Generics
  • Ottawa Reacts to Lead Scare
  • Recent Cases

Health Canada Reminds Consumers About the Risks of Buying Drugs Online

By: Roger Tam

On August 15, 2007, Health Canada issued a bulletin reminding Canadians about the dangers of buying drugs online. This bulletin follows a British Columbia Coroner's report attributing the death of a woman to prescription drugs purchased online. The bulletin warns Canadians of drugs being shipped from sources outside of Canada, in terms of the financial risks, as well as the health risks posed by counterfeit drugs. The posting also offers tips on how to identify illegitimate internet pharmacies and counterfeit products.

For more information, please see:

U.K. Published New Guidelines for Early Stage-Clinical Trials

By: Scott Robertson

The Association of the British Pharmaceutical Industry (ABPI) has published new clinical testing guidelines. The new guidelines are intended to provide more suitable advice on dosages and patient selection in the administration of early-stage clinical trials. ABPI Director General Richard Barker stated that the, "Safety of volunteers for Phase 1 clinical trials is paramount, and this is at the heart of the revised guidelines,"

The guidelines have been produced in consultation with stakeholders, clinical experts and industry best practices.

For more information, please see:

Apotex AIDS Drug Costlier than Other Generics

By: Marc Richard

As noted by a University of Ottawa Professor, Apotex is selling a drug to treat AIDS to Rwanda at a price which is much higher than other available generics from different countries. This brings into question whether Apotex' agreement to provide the drug through Canada's compassionate patent licensing scheme is the best option.

For more information, please see:

Ottawa Reacts to Lead Scare

By: John Norman

In recent weeks, Chinese manufactured products such as toothpaste, pet food, children's toys and baby bibs have been reported to contain unacceptable levels of diethylene glycol, melamine, lead and other things. In response, the Health Minister Tony Clement has announced that the Federal Government is launching a sweeping review of safety standards, seeking to determine if there are any gaps in the authority of regulators to ensure product safety.

For more information, please see:

Recent Cases

By: Beverley Moore

Abbott v. Apotex; 55.2 Proceeding; July 17, 2007 - clarithromycin

The Court dismissed an application for prohibition. In doing so, the Court held that the applicant bears the legal burden of proving on a balance of probabilities that the allegations of invalidity are unjustified and that it had not done so.

The patents at issue related to two polymorphic forms of clarithromycin and processes by which they could be prepared. The Court found that one of the patents was invalid because the form of clarithromycin it claimed was already known. Thus, the innovator could not have a valid patent for that form even if it was produced by a novel process.

The second patent at issue was found invalid for obviousness. The innovator argued that although the form of clarithromycin was known, its use as an antibiotic was not known. The Court did not accept this argument. Instead, the Court found that the patent contained nothing to support the contention that the use of Form II clarithromycin was not known as an antibiotic. The Court found that the generic company had met its evidentiary burden showing that this use was obvious in light of the prior art, and as the innovator had not tendered evidence supporting its position, and as the innovator bears the onus of proof on the issues of validity, the innovator had not proven this allegation was unjustified.

The full text of the decision can be found at:

Abbott v. Minister of Health; Listing Case; July 31, 2007 - lansoprazole

The Court granted the application for judicial review and concluded that the patent at issue meets the eligibility requirements and should not have been removed by the Minister from the Patent Register.

The Minister had made a decision to remove the patent at issue from the Patent Register in respect of an SNDS under his obligations to maintain the Patent Register. The patent at issue had been allowed on May 12, 2006 but had not actually issued until June 18, 2006. The date for considering the listability of patents in respect of the New Regulations was June 17, 2006.

The Court did not accept the Applicant's submissions with regards to vested rights and delay. Further, the Court did not accept that the Regulations do not allow the Minister to delete patents from the Patent Register.

However, the Court did find that the patent was eligible for listing under the New Regulations as it contains a claim for the new use of the medicine found in the SNDS. The SNDS specifically added the new use for treatment of NSAID ulcers. The patent claimed the use of the compound for the treatment of ulcers generally. The expert evidence indicated that a person skilled in the art would clearly understand that an NSAID ulcer is a type of ulcer and a skilled chemist would interpret the claims as covering any type of stomach ulcer, however caused.

Furthermore, the Court found simply because a patent includes claims for polymorphic forms of the medicine, does not disqualify it for listing. As the patent contains a claim for the changed use, it is eligible in spite of the fact that it also contains claims for polymorphic forms.

The full text of the decision can be found at:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions